Thus, anti-TNF-α antibodies such as infliximab, adalimumab, certolizumab pegol, and golimumab have been widely used for the treatment of IBD [15], with enhanced therapeutic efficacy even in severe stages of IBD, while also limiting systemic toxicity [16,17,18,19]. This evidence concerns the gene TNF and inflammatory bowel disease.